Topic resource collection
Approved comparison material connected to this topic.
33 resourcesRead both sides
The uniqueness of ACE-031 lies in its specific action mechanism. It targets myostatin and related proteins by binding to them, a distinct approach compared to other myostatin inhibitors. This selectivity stems from its fusion pro…
Follistatin exists in two principal isoforms: FST-288 (288 amino acids, ~31 kDa) and FST-315 (315 amino acids, ~35 kDa), generated by alternative splicing. FST-288 binds heparan sulphate proteoglycans (HSPGs) on the cell surface …
Direct comparative studies between Follistatin and ACE-031 in rodent models reveal: Both agents produce substantial dose-dependent increases in skeletal muscle mass The magnitude of muscle hypertrophy is comparable between the tw…
Follistatin and ACE-031 (modified ActRIIB-Fc) are supplied for research and laboratory use only. Neither is licensed for human therapeutic use in the UK. All findings described below derive from peer-reviewed preclinical research…
ACE-031’s broader ligand sequestration introduces off-target effects that Follistatin largely avoids. BMP9 and BMP10, which signal through ActRIIB and are sequestered by ACE-031, play important roles in vascular endothelial homeo…
Research question: myostatin-specific biology, mechanistic attribution, vascular-safe model, clean SMAD2/3 pathway → FST-315 10mg/kg 2×/week, pSMAD2/3 + atrogene controls, myostatin add-back reversal arm. Research question: maxim…
Two principal strategies for antagonising myostatin in research are Follistatin and ACE-031. Both promote muscle growth through myostatin inhibition, but they operate via distinct mechanisms with different pharmacological profile…
How does ACE-031 safety compare to related approaches? vs. Myostatin antibodies: Similar vascular safety concerns (epistaxis); ACE-031’s Fc region may provide slight advantage in tolerability vs. Follistatin: Both inhibit activin…
Compound Mechanism Muscle effect Key safety concern Status Soluble ActRIIB (ligand trap) Strong (+5.1% thigh volume) Vascular (BMP9/10) Discontinued 2013 ACE-083 Modified follistatin-Fc (local) Moderate (MRI increase) Lack of fun…
Perhaps the most surprising finding across the myostatin inhibitor field is that more muscle does not always mean better function. Both ACE-031 and ACE-083 produced measurable increases in muscle mass (by DXA and MRI), but neithe…
Researchers often want to know how ACE-031 compares to peptides with more established performance track records. The answer depends on what you are trying to achieve. For raw muscle mass gain, ACE-031 has the most impressive sing…
Putting ACE-031 side effects in context helps researchers assess relative risk. Compared to anabolic steroids, the side effect profile is fundamentally different. Steroids produce androgenic effects (acne, hair loss, virilization…
Live ACE-031 pricing — Current prices across all tracked vendors, normalized to price per milligram for a fair apples-to-apples comparison regardless of vial size. COA verification data — Third-party purity test results for ACE-0…